Shenzhen Salubris Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd., explained in plain language.
A Chinese pharmaceutical company developing cardiovascular and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a daily pill tame a hidden heart risk? Results expected Sep 2026 (estimated)
- Can a daily pill slash high lipoprotein(a) — a hidden heart risk with no approved treatment? Results expected Dec 2026 (estimated)
- New hope for stubborn high blood pressure: experimental drug SAL0140 enters phase 2 trial Results expected Mar 2027 (estimated)
- New drug SAL0140 aims to tame Hormone-Driven high blood pressure Results expected Apr 2027 (estimated)
- Can a new pill tame high cholesterol? a phase 1 trial puts SAL0167 to the test Results expected Jul 2027 (estimated)
-
Can a daily pill tame a hidden heart risk?
Disease control OngoingThis early-stage trial tests an experimental oral drug called SAL0137 in healthy adults, some with elevated Lp(a), a genetic risk factor for heart disease. The study aims to check the drug's safety, how the body processes it, and its effect on Lp(a) levels. Participants receive e…
Phase 1 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug aims to reduce kidney damage in chronic disease
Disease control OngoingThis clinical trial tests an experimental drug called SAL0120 in people with chronic kidney disease (CKD). The study aims to see if different doses of SAL0120 can reduce protein in the urine, a key marker of kidney damage. Participants are randomly assigned to receive either SAL0…
Phase 2 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New osteoporosis drug copycat tested in healthy volunteers
Disease control By invitation onlyThis study tests whether a new drug called SAL023 works like the approved osteoporosis medicine Evenity. It involves 118 healthy Chinese adults who get a single dose of either SAL023 or Evenity. The goal is to compare how the body processes the drug, its safety, and any immune re…
Phase 1 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC